Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amneal Pharmaceuticals (AMRX), Alnylam Pharma (ALN...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amneal Pharmaceuticals (AMRX), Alnylam Pharma (ALNY) and Biogen (BIIB)

Alnylam Pharmaceuticals ($ALNY) announced an update on their ongoing clinical study. Alnylam Pharmaceuticals (ALNY) is launching a Phase 2 study ti...

Alnylam Targets Down Syndrome-Linked Alzheimer’s With New Phase 2 Mivelsiran Trial

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intuitive Surgical (ISRG), Alnylam Pharma (ALNY) a...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intuitive Surgical (ISRG), Alnylam Pharma (ALNY) and Esperion (ESPR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immuneering (IMRX), Vera Therapeutics (VERA) and A...

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Vera Therapeutics (VERA) and Alnylam Pharma (ALNY)

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Alnylam Pharma, with a price target of $527.00. According to TipR...

Alnylam Pharma (ALNY) Receives a Buy from Barclays

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BridgeBio Pharma (BBIO), Healthequity (HQY) and Alny...

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Healthequity (HQY) and Alnylam Pharma (ALNY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ionis Pharmaceuticals (IONS) and Alnylam Pharma (ALN...

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Alnylam Pharma (ALNY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY), Molecular Partners (MOLN) a...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Molecular Partners (MOLN) and Exelixis (EXEL)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision ...

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biohaven Ltd. (BHVN) and Praxis Precision Medicines (PRAX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (ALNY) and Cytokinetics (CYTK) with b...

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Cytokinetics (CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alumis Inc. (ALMS) and Alnylam Pharma (ALNY) with bu...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ALNY	$271.77	+1.13%	1.15M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ALNY	$271.77	+1.1%	1.15M
3
4
5
6

ALNY

ALNY

Get Alnylam Pharmaceuticals Inc. Data in Excel

Get Alnylam Pharmaceuticals Inc. Data in Excel